LONDON, Sept. 8 /PRNewswire-FirstCall/ -- GlaxoSmithKline plc (GSK)
today announced that Chris Viehbacher, Executive Director and President
North American Pharmaceuticals, has decided to stand down from the Board on
8th September, and will leave the company with effect from 1st December
2008 to pursue another opportunity.
Andrew Witty, Chief Executive Officer said: "I would like to thank
Chris for his significant contribution to GSK, he is one of the most
talented and respected executives in this industry and we wish him well in
his future endeavors."
GlaxoSmithKline -- one of the world's leading research-based
pharmaceutical and healthcare companies -- is committed to improving the
quality of human life by enabling people to do more, feel better and live
longer. For further information please visit http://www.gsk.com
Cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities
Litigation Reform Act of 1995, GSK cautions investors that any
forward-looking statements or projections made by GSK, including those made
in this announcement, are subject to risks and uncertainties that may cause
actual results to differ materially from those projected. Factors that may
affect GSK' s operations are described under 'Risk Factors' in the
'Business Review' in the company' s Annual Report on Form 20-F for 2007.
SOURCE GlaxoSmithKline
 back to top
Related links:
http://www.gsk.com/
http://www.prnewswire.com/comp/801350.html/
CONTACT:
UK Media enquiries: Philip Thomson, or Claire
Brough, or Alice Hunt, or Gwenan White, +1-020-8047-5502; US
Media enquiries: Nancy Pekarek or Sarah Alspach, +1-215-751-7709,
or Mary Anne Rhyne, +1-919-483-2839; European Analyst-Investor
enquiries: David Mawdsley, +1-020-8047-5564, Sally Ferguson,
+1-020-8047-5543, or Gary Davies, +1-020-8047-5503; US
Analyst-Investor enquiries: Frank Murdolo, +1-215-751-7002, or
Tom Curry, +1-215-751-5419, all of GlaxoSmithKline
|
